Drug Development in Tissue-Agnostic Indications

Area of Science:

• Oncology
• Molecular Biology
• Drug Development

Background:

• Cancer biology understanding has spurred targeted therapies modulating cancer cells or microenvironment.
• Traditional oncology drug development, often using randomization, faces challenges with rare cancers and increasing molecular segmentation.
• Smaller patient subgroups benefiting from specific therapies necessitate new evaluation methods.

Purpose of the Study:

• To address the need for novel efficacy evaluation methods in small patient populations for targeted therapies.
• To explore alternative approaches to traditional randomization in oncology drug development.
• To facilitate tissue-agnostic drug development by overcoming patient heterogeneity.

Main Methods:

• Discusses the limitations of traditional randomization in oncology drug development for small patient cohorts.
• Proposes using each patient as their own control by comparing new drug efficacy to prior treatments.
• Highlights the potential of within-patient comparisons to address patient heterogeneity.

Main Results:

• Traditional randomization is challenging for rare cancers and molecularly defined subgroups.
• Using patients as their own controls offers a viable alternative for evaluating drug efficacy in small populations.
• This approach can overcome patient heterogeneity, crucial for tissue-agnostic drug development.

Conclusions:

• Novel methods for evaluating drug efficacy are essential for targeted therapies in small patient populations.
• Employing a within-patient control design can overcome challenges posed by patient heterogeneity.
• This strategy supports the advancement of tissue-agnostic drug development paradigms in oncology.